Wednesday, July 2, 2025 7/2/2025

Investigating the Role of p21-Highly Expressing Senescent Cells in Alzheimer's Dementia

Award Number: F30AG081092
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 04/15/2023
PERIOD OF PERFORMANCE END DATE: 04/14/2025

Group Awards By:

View Award Description

Investigating the Role of p21-Highly Expressing Senescent Cells in Alzheimer's Dementia - PROJECT SUMMARY/ABSTRACT Alzheimer’s Dementia (AD) is a leading cause of morbidity and mortality that is incompletely understood and lacking effective treatment. Accumulation of senescent cells (SnCs) has recently been implicated in AD pathogenesis and targeted removal of these cells may offer new therapeutic avenues. Cellular senescence is a cell fate defined by stable proliferative arrest, apoptotic resistance, and production of a pro-inflammatory secretome. Though senescence programming can contribute to proper development and regenerative processes, its dysregulation is increasingly linked with disease burden and pathology, including AD. While SnC modulation and clearance is a promising therapeutic target, it is increasingly clear that these cells are highly heterogeneous in their characteristics and function. We recently developed a mouse model to characterize a unique population of SnCs that highly express the cell cycle blockade protein p21 (p21high cells) and demonstrated that these cells play a causal role in age related physical dysfunction and metabolic disease. Furthermore, other literature has implicated clearance of pan-SnCs, which include p21high subpopulations, with cognitive improvements in AD. However, it is unknown if p21high cells make distinct contributions to AD or if their targeted removal can further counteract AD pathology. Therefore, this proposal aims to investigate the specific contributions of p21high SnCs to AD. Preliminary experiments have demonstrated that p21high cells accumulate in the brain of mouse AD models featuring amyloid- β plaque. However, it is unknown when these cells begin to accumulate in relation to the underlying disease process and what cell types are undergoing senescence. Therefore, in Aim 1, we will define the precise timeline of p21high cell accumulation in relation to amyloid- β plaque deposition (1A) and determine what cell types these represent (1B) by tracking these cells with a transgenic fluorescence reporter system and immunohistochemistry. To understand if these p21high SnCs play a causal role in AD, in Aim 2 we propose to selectively eliminate these cells via an inducible suicide gene to determine if targeted removal of these cells can either prevent (2A) or alleviate (2B) AD associated amyloid- β plaque formation and impaired performance on cognitive assays. We will also conduct single nuclei RNA sequencing (2C) on brains with or without p21high cell elimination to assess for changes in AD associated neuro-inflammatory pathways and explore underlying disease mechanisms associated with p21high cells. These aims will help to define the role of p21high SnCs in AD and may serve as a basis for new targeted disease modulating therapy. Furthermore, these results will further implicate p21high cells in age related disease and broaden the field’s appreciation of SnC heterogeneity. This work is part of a tailored career development plan at UConn Health that integrates training in aging biology, computational analysis, scientific communication, mentorship, clinical practice, and more to advance my career as a future physician-scientist that studies the drivers of aging.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	UNIVERSITY OF CONNECTICUT HEALTH CENTER	263 FARMINGTON AVE	FARMINGTON	CT	06030	CAPITOL	USA	Aging Research	000	2	3/26/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $45,187 )
2024	2024	UNIVERSITY OF CONNECTICUT HEALTH CENTER	263 FARMINGTON AVE	FARMINGTON	CT	06030	CAPITOL	USA	Aging Research	000	2	5/3/2024	NON-COMPETING CONTINUATION	$45,187
														Subtotal = $45,187

Issue Date FY: 2023 ( Subtotal = $43,216 )
2023	2023	UNIVERSITY OF CONNECTICUT	263 FARMINGTON AVE, ASB #3	FARMINGTON	CT	06032	CAPITOL	USA	Aging Research	002	1	2/15/2023	NEW	$0
2023	2023	UNIVERSITY OF CONNECTICUT	263 FARMINGTON AVE, ASB #3	FARMINGTON	CT	06032	CAPITOL	USA	Aging Research	000	1	12/8/2022	NEW	$42,274
2023	2023	UNIVERSITY OF CONNECTICUT	263 FARMINGTON AVE, ASB #3	FARMINGTON	CT	06032	CAPITOL	USA	Aging Research	001	1	2/15/2023	NEW	$942
														Subtotal = $43,216

Grand Total All Awards = $88,403

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Investigating the Role of p21-Highly Expressing Senescent Cells in Alzheimer's Dementia

Award Number: F30AG081092

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 04/15/2023

PERIOD OF PERFORMANCE END DATE: 04/14/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer